Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Anti-CD19 IL-10/IL15 CAR-NK Cells(The Second Affiliated Hospital Zhejiang University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Anti-CD19 IL-10/IL15 CAR-NK Cells(The Second Affiliated Hospital Zhejiang University): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical de
9 min read
DF-2755A Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
DF-2755A: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ABBV-969 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
ABBV-969: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
AMG-691 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
AMG-691: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
SP-8008 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
SP-8008: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
JWCAR-129 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
JWCAR-129: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
AZD-8186 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
AZD-8186: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Sleep apnoea therapy(Bayer AG) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
Sleep apnoea therapy(Bayer AG): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key
9 min read
ORB-011 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
ORB-011: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
XAGE-1 derived peptide vaccine(Kawasaki Medical School) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
XAGE-1 derived peptide vaccine(Kawasaki Medical School): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals,
9 min read
SK-1887 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
SK-1887: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
OSSM-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
14 October 2026
OSSM-001: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.